Adler, L. A., Angrist, B., Retter, S., et al (1989) Neuroleptic-induced akathisia: a review. Psychopharmacology, 97, 1–11.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) . Washington, DC: APA.
Barnes, T. R. E. (1989) A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672–676.
Barnes, T. R. E. & McPhillips, M. A. (1999) Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. British Journal of Psychiatry, 174 (suppl. 38), 34–43.
D'Mello, D. A., McNeil, J. A. & Harris, W. (1989) Buspirone suppression of neuroleptic-induced akathisia: multiple case reports (letter). Journal of Clinical Psychopharmacology, 9, 151–152.
Fischel, T., Hermesh, H., Alzenberg, D., et al (2001) Cyproheptadine vs. propranolol for the treatment of acute neuroleptic-induced akathisia: A comparative double-blind study. Journal of Clinical Psychopharmacology, .
Fleischhacker, W. W., Roth, S. D. & Kane, J. M. (1990) The pharmacologic treatment of neuroleptic-induced akathisia. Journal of Clinical Psychopharmacology, 10, 12–21.
Kapur, S. & Remington, G. (1996) Serotonin – dopamine interaction and its relevance to schizophrenia. American Journal of Psychiatry, 153, 466–476.
Lane, R. M. (1998) SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. Journal of Psychopharmacology, 12, 192–214.
Leysen, J. E., Gommeren, W. & Shotte, A. (1996) Serotonin receptor subtypes: possible roles and applications in antipsychotic drug action. In Serotonin in Antipsychotic Treatment. Mechanisms and Clinical Practice (eds Kane, J. M., Moller, H.-J. & Awouters, F.), pp. 51–75. New York: Marcel Dekker.
Meltzer, H. Y. (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology, 21 (suppl. 2), 106S–115S.
Miller, G. H., Fleischhacker, W. W., Ehrman, H., et al (1990) Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacology Bulletin, 26, 373–376.
Miller, C. H., Hummer, M., Pycha, R., et al (1992) The effect of ritanserin on treatment-resistant neuroleptic-induced akathisia: case reports. Progress in Neuropsychopharmacology and Biological Psychiatry, 16, 247–251.
Poyurovsky, M. & Weizman, A. (1997) Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin. International Clinical Psychopharmacology, 12, 263–268.
Poyurovsky, M. & Weizman, A. (1999) Lack of efficacy of the 5-HT3 receptor antagonist granisetron in the treatment of acute neuroleptic-induced akathisia. International Clinical Psychopharmacology, 14, 357–360.
Poyurovsky, M. & Weizman, A. (2001) Low dose mirtazapine ameliorates acute neuroleptic-induced akathisia (letter). American Journal of Psychiatry, .
Poyurovsky, M., Fuchs, C. & Weizman, A. (1998) Low-dose mianserin in the treatment of acute neuroleptic-induced akathisia. Journal of Clinical Psychopharmacology, 18, 253–254.
Poyurovsky, M., Shardorodsky, M., Fuchs, C., et al (1999) Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study. British Journal of Psychiatry, 174, 238–242.
Richelson, E. (1996) Preclinical pharmacology of neuroleptics; focus on new generation compounds. Journal of Clinical Psychiatry, 57 (suppl. 11), 4–10.
Seeman, P. & Tallerico, T. (1998) Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors yet occupy high levels of these receptors. Molecular Psychiatry, 3, 123–134.
Weiss, D., Aizenberg, D., Hermesh, H., et al (1995) Cyproheptadine treatment in neuroleptic-induced akathisia. British Journal of Psychiatry, 167, 483–486.
Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: A new approach to an old problem
eLetters
No eLetters have been published for this article.